The FDA is reviewing a gene therapy treatment developed in Iowa.
The clinical trial drew people seeking treatment for a rare blindness called leber congenital amaurosis, including Molly Troxel of Omaha. Before the treatment can be offered to the public, the FDA has to carefully review the study and results.
After initial hesitation, Molly's parents sought the treatment, and they say the results have been incredible.
In January, the FDA will make its final decision after reviewing the study last month.
